<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>&lt;i&gt;Mycoplasma pneumoniae&lt;/i&gt; infection in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center"><i>Mycoplasma pneumoniae</i> infection in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle"><i>Mycoplasma pneumoniae</i> infection in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jesus G Vallejo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Mycoplasma pneumoniae</em> is one of the few species of <em>Mycoplasma</em> that frequently cause infection in humans. <em>M. pneumoniae</em> predominantly causes respiratory tract infection but has a wide variety of clinical manifestations.</p><p>The clinical features, diagnosis, and treatment of <em>M. pneumoniae</em> infection in children will be reviewed here. <em>M. pneumoniae</em> infection in adults, <em>Mycoplasma genitalium, Mycoplasma hominis, </em>and<em> Ureaplasma urealyticum</em> infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection"</a> and  <a class="medical medical_review" href="/z/d/html/5508.html" rel="external">"<i>Mycoplasma hominis</i> and <i>Ureaplasma </i>infections"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The term "mycoplasma" is used to refer to any organism within the class Mollicutes, which is composed of five genera (<em>Mycoplasma</em>, <em>Ureaplasma</em>, <em>Acholeplasma</em>, <em>Anaeroplasma</em>, and <em>Asteroloplasma</em>).</p><p><em>M. pneumoniae</em> lacks a cell wall, which differentiates it from other pathogenic bacteria [<a href="#rid1">1</a>]. Although it grows under both aerobic and anaerobic conditions and can be isolated on media supplemented with serum, it is a fastidious organism, and isolation is not commonly performed in clinical laboratories.</p><p>The mechanisms by which mycoplasmas produce infection are becoming better understood. They include direct effects of the bacteria, indirect immune-mediated effects, and effects mediated through vasculitis or thrombosis secondary to cytokines, chemokines, or immunomodulation [<a href="#rid2">2,3</a>].</p><p>Pathogenic mycoplasmas have specialized tip organelles that mediate their interactions with host cells through transmembrane proteins (eg, P1, P30) that contribute to adherence and gliding motility along the respiratory epithelium [<a href="#rid2">2,4-7</a>]. Toll-like receptor 2 is also believed to be important for binding of <em>Mycoplasma</em> and activation of inflammatory mediators, including cytokines [<a href="#rid8">8-10</a>].</p><p>The adherence proteins of <em>M. pneumoniae </em>have a particular affinity for respiratory tract epithelium [<a href="#rid11">11,12</a>]. Once attached, <em>M. pneumoniae</em> produces hydrogen peroxide and superoxide, causing injury to epithelial cells and their associated cilia. Survival is achieved by surface parasitism of target cells, acquisition of essential biosynthetic precursors, and, in some cases, cell entry and intracellular survival [<a href="#rid13">13</a>]. After acute infection, prolonged asymptomatic carriage may be mediated by intracellular invasion, bacterial-induced cytoskeleton rearrangement, and tissue remodeling [<a href="#rid14">14-16</a>].</p><p>The clinical manifestations of <em>M. pneumoniae</em> infection are affected by the immune competence and immune response of the host, suggesting that some of the pathogenic features of <em>M. pneumoniae</em> infection, particularly extrapulmonary manifestations (eg, hemolysis, encephalitis), are immune mediated [<a href="#rid2">2,12</a>]. The antibodies produced against the glycolipid antigens of <em>M. pneumoniae</em> cross-react with human red cells and brain cells and may act as autoantibodies [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H4224001494"><span class="h1">TRANSMISSION</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> is transmitted from person to person by infected respiratory droplets during close contact. The incubation period after exposure is approximately 23 days [<a href="#rid2">2</a>]. The cumulative attack rate in families approaches 90 percent [<a href="#rid18">18</a>]. Immunity is not long-standing, although immunoglobulin (Ig)G antibodies may persist for years [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> infection occurs most frequently during the summer and early fall but may develop year-round [<a href="#rid2">2,19</a>].</p><p><em>M. pneumoniae</em> infection occurs in children of all ages. In a series of 353 children hospitalized with <em>M. pneumoniae</em> infection between 2007 and 2017, approximately one-half of patients were &lt;6 years old [<a href="#rid20">20</a>]. In population-based surveillance, the rate of hospitalization for <em>M. pneumoniae</em> pneumonia among children (&lt;18 years) was 1.4 per 10,000 children per year and was similar across age groups [<a href="#rid21">21</a>].</p><p><em>M. pneumoniae</em> is a common cause of community-acquired pneumonia (CAP) in children. In population-based surveillance from 2010 to 2012, <em>M. pneumoniae</em> was the most frequently detected bacterial pathogen in &gt;2200 children (age &lt;18 years) hospitalized with radiographically confirmed CAP in the United States, accounting for 8 percent of cases [<a href="#rid21">21,22</a>].</p><p>The relative importance of <em>M. pneumoniae</em> as a cause of CAP in children increases during the school-age years (even though the overall incidence of pneumonia declines). In prospective population-based surveillance, the median age of children hospitalized with CAP was 7 years [<a href="#rid22">22</a>]. The proportion of cases caused by <em>M. pneumoniae</em> increased with age (2 percent in children age &lt;2 years, 5 percent in children age 2 to 4 years, 16 percent in children age 5 to 9 years, and 23 percent in children age 10 to 17 years) [<a href="#rid21">21</a>].</p><p>Other pathogens are frequently detected in children with <em>M. pneumoniae</em> infection [<a href="#rid22">22-24</a>]. In two reviews of children hospitalized with <em>M. pneumoniae</em>, codetection of viral pathogens occurred in approximately 30 percent of children, most frequently in children younger than two to five years. Viral copathogens may account for some of the clinical manifestations attributed to <em>M. pneumoniae</em> in young children [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> causes a wide spectrum of illness [<a href="#rid25">25</a>]. Many <em>M. pneumoniae</em> infections are asymptomatic [<a href="#rid14">14,26</a>]. The clinical manifestations of symptomatic <em>M. pneumoniae</em> infection are typically divided into respiratory tract (most common) and extrapulmonary manifestations (less common) [<a href="#rid2">2,26</a>]. None of the manifestations is unique to <em>M. pneumoniae</em> [<a href="#rid27">27,28</a>]. Although <em>M. pneumoniae</em> infections generally are mild and self-limiting, patients of all ages can develop severe community-acquired pneumonia (CAP) or extrapulmonary manifestations [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H849531243"><span class="h2">Asymptomatic carriage</span><span class="headingEndMark"> — </span>Asymptomatic carriage is common and may play a role in <em>M. pneumoniae</em> transmission [<a href="#rid14">14,15,29</a>]. Following symptomatic infection, asymptomatic carriage of <em>M. pneumoniae</em> can persist for weeks to months, even in patients who received antimicrobial therapy [<a href="#rid14">14,15,30</a>]. In studies using polymerase chain reaction (PCR)-based assays, the reported rates of <em>M. pneumoniae</em> detection in the respiratory secretions of children range from ≤3 to 56 percent [<a href="#rid14">14,21,31,32</a>]. The wide range may be due to different definitions for asymptomatic controls, testing methods, and <em>M. pneumoniae</em> activity with time and geographic location. </p><p class="headingAnchor" id="H2170752561"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>Pneumonia is the most common clinical manifestation of <em>M. pneumoniae</em> in school-age children [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The signs and symptoms of <em>M. pneumoniae</em> pneumonia vary according to the stage of illness  (<a class="graphic graphic_figure graphicRef59329" href="/z/d/graphic/59329.html" rel="external">figure 1</a>). The onset is gradual and usually is heralded by headache, malaise, and low-grade fever [<a href="#rid17">17,26</a>]. Physical examination abnormalities are often minimal.</p><p></p><p class="bulletIndent1">Among children with PCR-documented, radiographically confirmed <em>M. pneumoniae</em> pneumonia in two studies, commonly reported symptoms and signs included [<a href="#rid20">20,22</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever (86 to 96 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Cough (85 to 96 percent); cough is usually nonproductive and may persist for weeks to months [<a href="#rid19">19,28</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Fatigue (78 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Dyspnea (67 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Headache (11 to 48 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Sore throat (12 to 47 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal auscultation (75 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Extrapulmonary manifestations (26 percent)</p><p></p><p class="bulletIndent1">Clinical features that were more frequently associated with <em>M. pneumoniae</em> than other pathogens include age 5 through 17 years, rales, decreased breaths sounds, headache, and sore throat [<a href="#rid22">22</a>]. However, these findings are nonspecific and do not definitively distinguish <em>M. pneumonia</em> from other CAP pathogens [<a href="#rid22">22,28</a>].</p><p></p><p class="bulletIndent1">Other clinical findings related to the respiratory tract include sinus tenderness, rhinorrhea, mild erythema of the posterior pharynx, ear pain, erythema or bullae of the tympanic membrane, and nonprominent cervical adenopathy [<a href="#rid20">20,26</a>].</p><p></p><p class="bulletIndent1"><em>M. pneumoniae</em> CAP can be severe [<a href="#rid33">33,34</a>]. In a prospective study of 182 children (age &lt;18 years) with <em>M. pneumoniae</em> CAP, 26 percent had pleural effusion and 12 percent required intensive care [<a href="#rid22">22</a>]. Empyema is a rare complication of <em>M. pneumoniae</em> pneumonia [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/6344.html" rel="external">"Epidemiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children"</a> and  <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">"Management and prognosis of parapneumonic effusion and empyema in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic findings</strong> – Radiographic findings of <em>M. pneumoniae</em> pneumonia are variable, nonspecific, and may be difficult to appreciate [<a href="#rid20">20,22,36</a>].</p><p></p><p class="bulletIndent1">In a prospective study of 182 children (age &lt;18 years) hospitalized with <em>M. pneumoniae </em>CAP, radiographic findings (which were not mutually exclusive) included consolidation (59 percent), single lobar infiltrate (32 percent), unilateral multilobar infiltrates (11 percent), bilateral multilobar infiltrates  (<a class="graphic graphic_diagnosticimage graphicRef86363" href="/z/d/graphic/86363.html" rel="external">image 1</a>) (12 percent), pleural effusion (26 percent), and hilar adenopathy (10 percent) [<a href="#rid22">22</a>]. The finding of hilar adenopathy in children with suspected <em>M. pneumoniae</em> infection should also prompt consideration of tuberculosis. (See  <a class="medical medical_review" href="/z/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Although high-resolution computed tomography may be more sensitive than chest radiography for detection of air space abnormalities in patients with <em>M. pneumoniae</em> pneumonia [<a href="#rid36">36</a>], it is not necessary in the routine evaluation. Given the radiation exposure, it should only be obtained if the results will affect management. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging", section on 'Children and adolescents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings </strong>– Laboratory findings in children with <em>M. pneumoniae </em>pneumonia are nonspecific.</p><p></p><p class="bulletIndent1">The total white blood cell count, neutrophil count, and platelet count may be slightly elevated [<a href="#rid2">2,20</a>]. In a review of 182 cases of PCR-documented <em>M. pneumoniae</em> pneumonia in children, 25 percent had leukocytosis and 9 percent had thrombocytosis [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) also may be elevated [<a href="#rid2">2,20</a>]. In a cohort of 194 children with radiographically confirmed <em>M. pneumoniae</em> pneumonia, the median ESR was 51 mm/h (interquartile range [IQR] 23 to 73 mm/h) and the median CRP was 4 mg/dL (IQR 2 to 8 mg/dL) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Some patients have subclinical evidence of hemolytic anemia (eg, positive Coombs test, elevated reticulocyte count). (See <a class="local">'Hemolysis'</a> below.)</p><p></p><p class="headingAnchor" id="H3084015914"><span class="h2">Other respiratory manifestations</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> may cause a nonspecific respiratory illness similar to an upper respiratory tract infection (eg, nonexudative sore throat, coryza, headache, ear pain, prolonged cough) [<a href="#rid2">2,20</a>].</p><p><em>M. pneumoniae</em> infection can worsen asthma symptoms and may be associated with wheezing in children who do not have asthma [<a href="#rid2">2,20,22</a>]. Whether <em>M. pneumoniae</em> has a pathogenic role in asthma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Respiratory infections'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Extrapulmonary manifestations</span><span class="headingEndMark"> — </span>Extrapulmonary manifestations may occur with respiratory manifestations or independently [<a href="#rid19">19,20</a>]. When present, they support the diagnosis. In a review of children hospitalized with PCR-documented <em>M. pneumoniae</em> infection, 26 percent of the 332 children with complete clinical information had extrapulmonary manifestations; 11 percent had only extrapulmonary manifestations [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Hemolysis</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em>-associated hemolysis usually is not clinically significant, although it can be severe, particularly in patients with underlying sickle cell disease [<a href="#rid17">17,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis"</a>.)</p><p>IgM antibodies to the I antigen on erythrocyte membranes appear during the course of mycoplasma infection and produce a cold agglutinin response in approximately 50 percent of patients [<a href="#rid2">2</a>]. Why mycoplasma infections promote the production of such antibodies and their significance in pathogenesis is not known. (See <a class="local">'Laboratory tests'</a> below and  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Mucocutaneous disease</span><span class="headingEndMark"> — </span>Mucosal or cutaneous eruptions are a common extrapulmonary manifestation of <em>M. pneumoniae</em> infection, occurring in as many as 25 percent of patients [<a href="#rid20">20,38,39</a>].</p><p>Dermatologic manifestations range from a mild erythematous maculopapular or vesicular rash (which is most commonly seen accompanying respiratory tract infections), to bullous papular purpuric gloves and socks syndrome, to reactive infectious mucocutaneous eruption (a Stevens-Johnson-like syndrome) [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Central nervous system manifestations</span><span class="headingEndMark"> — </span>Central nervous system (CNS) manifestations occur in approximately 0.1 percent of all patients with <em>M. pneumoniae</em> infections and approximately 6 percent hospitalized patients [<a href="#rid2">2,20,40</a>].</p><p>CNS involvement occurs most frequently in children and includes [<a href="#rid20">20,41-51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Meningoencephalitis (which may be complicated by postencephalitic epilepsy)</p><p class="bulletIndent1"><span class="glyph">●</span>Acute disseminated encephalomyelitis (ADEM)</p><p class="bulletIndent1"><span class="glyph">●</span>Transverse myelitis</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar ataxia</p><p class="bulletIndent1"><span class="glyph">●</span>Guillain-Barré syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar infarct</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy</p><p class="bulletIndent1"><span class="glyph">●</span>Cranial nerve palsies</p><p></p><p>In patients with CNS involvement, the cerebrospinal fluid (CSF) typically reveals a lymphocytic pleocytosis, elevated protein, and normal glucose [<a href="#rid50">50</a>]. Detection of <em>M. pneumoniae</em> in the CSF occurs relatively infrequently [<a href="#rid40">40,52,53</a>].</p><p>In a retrospective study of 365 children with <em>M. pneumoniae</em> detected in the CSF or respiratory tract by PCR between 1996 and 2013, neurologic disease was attributable to <em>M. pneumoniae</em> in 11.5 percent [<a href="#rid47">47</a>]. Among the 42 children with neurologic disease, encephalitis, ADEM, transverse myelitis, and cerebellar ataxia were most common. CSF PCR was positive for <em>M. pneumoniae</em> in 14 of the 35 children in whom it was obtained. Two distinct patterns of neurologic disease were noted: a prodrome of ≥7 days, respiratory manifestations, chest radiograph abnormalities, reactive IgM in acute serum, and detection of <em>M. pneumoniae</em> in the respiratory tract, but not the CSF; and a prodrome of &lt;7 days, fewer respiratory manifestations, nonreactive IgM response, and detection of <em>M. pneumoniae</em> in the CSF only.</p><p>Although uncommon, CNS involvement is associated with significant morbidity and mortality [<a href="#rid40">40,47,50</a>]. In the retrospective study described above, 20 of 42 children with <em>M. pneumoniae</em> neurologic disease had adverse neurologic outcomes (eg, epilepsy, focal neurologic deficits, persistent headaches), but no deaths were reported [<a href="#rid47">47</a>]. In another retrospective study of 61 patients with <em>M. pneumoniae</em> neurologic disease, 14 had severe sequelae and 8 patients died [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Other manifestations</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> can also cause gastrointestinal, rheumatologic, cardiac, and renal disease [<a href="#rid2">2,17,54</a>].</p><p>In a review of 353 children hospitalized with PCR-documented <em>M. pneumoniae</em> infection, 38 percent had abdominal pain, vomiting, and diarrhea; 10 percent had elevated liver enzymes; 3 percent had more serious gastrointestinal involvement (eg, splenomegaly, intussusception, hepatomegaly, pancreatitis); 3 percent had arthritis or arthralgia; and 4 percent had cardiovascular involvement (eg, heart failure, myocarditis, pericardial effusion) [<a href="#rid20">20</a>]. Clinically significant glomerulonephritis is a rare complication that is presumed to be secondary to immune complex deposition [<a href="#rid55">55-57</a>].</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1457828964"><span class="h2">Criteria for confirmation</span><span class="headingEndMark"> — </span><em>M. pneumoniae</em> should be suspected in children with a compatible clinical syndrome. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>Confirmation of <em>M. pneumoniae</em> requires detection of <em>M. pneumoniae</em> or antibody response to <em>M. pneumoniae</em> in conjunction with a compatible clinical syndrome. Laboratory results must be interpreted with caution because they may not differentiate between <em>M. pneumoniae</em> disease and asymptomatic colonization or clinical manifestations of a concomitant viral pathogen [<a href="#rid14">14,58-60</a>]. The diagnosis may be confirmed in retrospect (eg, by convalescent serology or clinical improvement with <em>M. pneumoniae</em>-specific therapy).</p><p class="headingAnchor" id="H3692244182"><span class="h2">Indications for testing</span><span class="headingEndMark"> — </span>Laboratory confirmation should only be pursued if it will alter management (eg, in patients with life-threatening disease, such as encephalitis, or if antimicrobial therapy is necessary and the empiric regimen does not include an agent with activity against <em>M. pneumoniae</em>, such as a macrolide, <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a>, or quinolone antibiotic). (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H1773744806"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>The approach to laboratory testing for <em>M. pneumoniae </em>varies with the clinical findings.</p><p class="headingAnchor" id="H4191240195"><span class="h3">Pneumonia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatients</strong> – Laboratory testing usually is not performed in outpatients with community-acquired pneumonia (CAP) because empiric treatment is almost always successful, whether or not it includes activity against <em>M. pneumoniae</em> [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Indications for microbiologic testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospitalized children</strong> – Laboratory testing for <em>M. pneumoniae</em> generally is warranted for children hospitalized with CAP, particularly if they have compromised immunity, risk factors (eg, close exposure during an outbreak), or associated extrapulmonary manifestations (eg, mucocutaneous eruption, hemolysis) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">Laboratory testing also may be warranted for hospitalized children who do not improve as expected with supportive care for presumed viral pneumonia or with beta-lactam antibiotics for presumed typical bacterial pneumonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing approach </strong>– When testing is necessary, we prefer <em>M. pneumoniae</em> polymerase chain reaction (PCR), including multiplex PCR panels, from a respiratory specimen (eg, nasopharyngeal or throat swab) [<a href="#rid63">63</a>]. PCR can be performed rapidly and has high sensitivity and specificity. If PCR is not available, serology (<em>M. pneumoniae</em> IgM and IgG enzyme immunoassay [EIA]) is a reasonable alternative<em>. M. pneumoniae</em> culture is not available in most clinical laboratories [<a href="#rid58">58</a>]. We do not routinely obtain cold agglutinin antibody titers or bedside cold agglutinins in children with pneumonia. (See <a class="local">'Laboratory tests'</a> below.)</p><p></p><p class="headingAnchor" id="H1037619576"><span class="h3">Mucocutaneous disease</span><span class="headingEndMark"> — </span>Detection of <em>M. pneumoniae</em> is necessary to definitively attribute mucocutaneous disease to <em>M. pneumoniae</em> [<a href="#rid64">64</a>]. Diagnosis of reactive infectious mucocutaneous eruption (RIME) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)", section on 'Diagnosis'</a>.)</p><p>If not already obtained, chest radiograph also may be warranted given the frequency of prodromal respiratory symptoms in patients with RIME. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1511871247"><span class="h3">Encephalitis</span><span class="headingEndMark"> — </span>Encephalitis is an acute, life-threatening emergency, and a systematic approach is necessary for prompt recognition and appropriate management. The complete evaluation is discussed in detail separately and summarized in the table  (<a class="graphic graphic_table graphicRef51779" href="/z/d/graphic/51779.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6042.html" rel="external">"Acute viral encephalitis in children: Clinical manifestations and diagnosis", section on 'Evaluation'</a>.)</p><p>Our approach to the evaluation for <em>M. pneumoniae</em> in children with encephalitis is consistent with that of the International Encephalitis Consortium [<a href="#rid65">65</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with respiratory symptoms </strong>– For children with suspected <em>M. pneumoniae</em> meningoencephalitis and concomitant respiratory symptoms, we obtain <em>M. pneumoniae</em> PCR from the throat and cerebrospinal fluid (CSF) and serology (<em>M. pneumoniae</em> IgM and IgG). (See <a class="local">'Laboratory tests'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children without respiratory symptoms</strong> – For children with suspected <em>M. pneumoniae</em> meningoencephalitis without respiratory symptoms, we obtain a throat sample for <em>M. pneumoniae</em> PCR and serology (<em>M. pneumoniae</em> IgM and IgG); we obtain CSF PCR only if either of the initial tests is positive. (See <a class="local">'Laboratory tests'</a> below.)</p><p></p><p class="headingAnchor" id="H4041759840"><span class="h3">Other extrapulmonary disease</span><span class="headingEndMark"> — </span>For other types of extrapulmonary disease, the confirmation of <em>M. pneumoniae</em> may be established by detection of <em>M. pneumoniae</em> at the affected site (eg, <em>M. pneumoniae</em> PCR from vesicular fluid, oral lesions, synovial fluid) or by the <em>M. pneumoniae</em> antibody response [<a href="#rid66">66-70</a>]. However, lack of detection or antibody response does not exclude the diagnosis [<a href="#rid14">14,58,59,71</a>].</p><p class="headingAnchor" id="H4204342151"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Available tests for acute diagnosis of <em>M. pneumoniae</em> include nucleic acid amplification tests (NAATs) and serology. Culture, performed in specialized reference laboratories, is not widely available. Each of these methods has <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpneumonia%2Fatypical%2Fmycoplasma%2Fhcp%2Fdiagnostic-methods.html&amp;token=45gUNXX%2B4jDq1kgqFe27vMaGYovMkiahEt%2BvjGqvllZ9mFc4cpnOirjyCvAZyTrHdZxE7lWCcxvc60VJuV8yPU4HW%2FJzOgKJzJRvbb7io4A%3D&amp;TOPIC_ID=6070" target="_blank">advantages and disadvantages</a> [<a href="#rid72">72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleic acid amplification tests</strong> –<strong> </strong>NAATs, including PCR-based assays, are highly sensitive and specific for <em>M. pneumoniae</em> in patients with respiratory tract infections and results are available in less than one day [<a href="#rid2">2,73,74</a>]. However, they may not reliably distinguish<em> </em>active<em> M. pneumoniae</em> infection from coinfection with other pathogens or from asymptomatic carriage [<a href="#rid14">14</a>]. (See <a class="local">'Asymptomatic carriage'</a> above.)</p><p></p><p class="bulletIndent1">Single and multiplex PCR assays for <em>M. pneumoniae</em> are commercially available for respiratory tract samples (eg, nasopharyngeal or throat swab, sputum sample, bronchoalveolar lavage fluid) [<a href="#rid63">63,72,75,76</a>]. Although the sensitivity and specificity of US Food and Drug Administration (FDA)-cleared assays is generally &gt;90 percent for respiratory samples (using various reference standards including serology, culture, or another NAAT) [<a href="#rid76">76-79</a>], the sensitivity and specificity of PCR assays that are used by individual institutions (which may not be cleared by the FDA) are not generalizable.</p><p></p><p class="bulletIndent1">Single and multiplex assays for <em>M. pneumoniae</em> in the CSF are also available, but the diagnostic yield of CSF PCR is low relative to serology. (See  <a class="medical medical_review" href="/z/d/html/1278.html" rel="external">"Molecular diagnosis of central nervous system infections", section on 'Bacteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serology</strong> – Serology is an adjunct to PCR or as an alternative to PCR if PCR is not available. IgM antibody titers begin to rise approximately seven to nine days after infection, peak at three to six weeks, and persist for months [<a href="#rid52">52</a>]. IgG antibody titers begin to rise and peak approximately two weeks after IgM titers and persist for years. Both IgM and IgG antibodies may be negative early in the disease course.</p><p></p><p class="bulletIndent1">In general, a fourfold or greater increase in titer in paired sera (separated by four weeks) is indicative of infection [<a href="#rid19">19</a>]; a single titer is not definitive for diagnosis, but convalescent titers are only necessary if they will change management [<a href="#rid80">80-82</a>].</p><p></p><p class="bulletIndent1">Although serologic tests provide evidence of infection, definitive diagnosis is delayed by the need to assay acute and convalescent serum. In addition, serologic tests may not distinguish <em>M. pneumoniae</em> disease from asymptomatic carriage [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Among the available serologic tests, EIA is preferred to complement fixation tests because EIA is more readily available and more specific [<a href="#rid52">52</a>]. EIA is more sensitive in detecting acute infection than culture and has sensitivity comparable to the PCR if there has been sufficient time to develop an antibody response [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">A number of studies evaluating commercially available serologic tests note a lack of comparability among the tests and among different laboratories [<a href="#rid82">82-85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antigen detection</strong> –Antigen detection can be performed by antigen capture-EIA (Ag-EIA), which may detect 10<sup>4</sup> colony-forming units/mL (a level which should be present in the majority of infections) [<a href="#rid86">86</a>]. Antigen detection tests have largely been replaced by molecular testing methods but continue to be used in some countries [<a href="#rid2">2</a>]. One problem with Ag-EIA is that the ability to detect antigen may vary with the time of sampling; the test is most often positive within seven days of onset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Culture</strong> – Most clinical laboratories do not attempt to culture <em>M. pneumoniae</em> [<a href="#rid58">58</a>]. Although isolation is possible, it takes two to three weeks and requires a specialized media. <em>M. pneumoniae</em> is not visible on Gram stain because it lacks a cell wall.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold agglutinins</strong> – The formation of cold agglutinins is a nonspecific early IgM reaction against the erythrocyte I antigen.</p><p></p><p class="bulletIndent1">We do not routinely obtain cold agglutinin antibody titers in children because the accuracy of cold agglutinins in detecting<em> M. pneumoniae</em> in children is not known [<a href="#rid58">58</a>], nor do we suggest performing bedside cold agglutinins because bedside cold agglutinins are neither sensitive nor specific for <em>M. pneumoniae</em> infection in children. A variety of other respiratory pathogens have been associated with increased cold agglutinins. (See  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Infections and autoimmune disorders'</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H103825114"><span class="h2">Pneumonia</span></p><p class="headingAnchor" id="H90904282"><span class="h3">Empiric therapy</span><span class="headingEndMark"> — </span>Initial treatment for <em>M. pneumoniae</em> pneumonia typically is initiated based on clinical suspicion. Confirmation of <em>M. pneumoniae</em> is often lacking because of the difficulty with definitive diagnosis early in the course of infection and because microbiologic testing is not recommended for community-acquired pneumonia (CAP) in children who are treated in the outpatient setting. Empiric treatment of CAP in children, including <em>M. pneumoniae</em> pneumonia, is discussed separately. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5987.html" rel="external">"Community-acquired pneumonia in children: Outpatient treatment", section on 'Empiric therapy'</a>.)</p><p class="headingAnchor" id="H1510099660"><span class="h3">Documented <i>M. pneumoniae</i></span><span class="headingEndMark"> — </span>For children with documented <em>M. pneumoniae </em>pneumonia, we suggest antimicrobial therapy with an agent with activity against <em>M. pneumoniae </em>(eg, macrolide, tetracycline, or fluoroquinolone antibiotics)<em>.</em> <em>M. pneumoniae</em> is resistant to antibiotics that inhibit cell wall synthesis (eg, beta-lactam antibiotics) [<a href="#rid19">19</a>]. Limited evidence suggests that <em>M. pneumoniae</em>-specific therapy may be associated with decreased rates of hospitalization or shorter length of stay.</p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompetent children we typically use a macrolide or tetracycline antibiotic for initial therapy. Fluoroquinolones are reserved for children in whom there is no safe or effective alternative [<a href="#rid87">87,88</a>]. The regimens are as follows [<a href="#rid58">58,89,90</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">Azithromycin</a> 10 mg/kg in one dose (maximum dose 500 mg) orally or intravenously (IV) on the first day and 5 mg/kg in one dose (maximum dose 250 mg) for the next four days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">Clarithromycin</a> 15 mg/kg per day orally in two divided doses (maximum daily dose 1 g) for 7 to 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">Doxycycline</a> 2 to 4 mg/kg per day orally or IV in one or two divided doses (maximum daily dose 200 mg) for 7 days.</p><p></p><p class="bulletIndent2">Compared with other tetracycline antibiotics, <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a> is unlikely to cause permanent tooth discoloration in young children [<a href="#rid91">91-94</a>]. It can be administered for ≤21 days to children of all ages [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">Erythromycin</a> 40 to 50 mg/kg per day orally in three or four divided doses (maximum daily dose 2 g) for 7 to 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">Erythromycin</a> 20 mg/kg per day IV in four divided doses (maximum daily dose 2 g) for 7 to 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥8 years of age – <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">Tetracycline</a> 25 to 50 mg/kg per day orally in four divided doses (maximum daily dose 2 g) for 7 to 10 days.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">Azithromycin</a>, <a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">clarithromycin</a>, <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a>, and <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> are preferred to <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">erythromycin</a> because they require less frequent dosing and have fewer gastrointestinal adverse effects. Azithromycin has a longer half-life than clarithromycin and usually is better tolerated [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompromised children, fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>) are an alternative initial agent, especially if the patient has a history of exposure to a macrolide antibiotic [<a href="#rid24">24</a>]. Fluoroquinolones are bactericidal rather than bacteriostatic. Dosing for levofloxacin varies according to age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥6 months and &lt;5 years – <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> 8 to 10 mg/kg per dose orally or IV every 12 hours (maximum daily dose 750 mg/day) for 7 to 10 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥5 years – <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> 10 mg/kg per dose once per day orally or IV (maximum daily dose 750 mg/day) for 7 to 10 days.</p><p></p><p>Macrolide, tetracycline, and fluoroquinolone antibiotics are active against<em> M. pneumoniae</em> in vitro, and macrolide antibiotics may have anti-inflammatory effects [<a href="#rid2">2</a>]. Macrolide and <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> antibiotics have a lower risk of severe adverse effects than fluoroquinolones.</p><p>Studies supporting antibiotic treatment of documented <em>M. pneumoniae</em> pneumonia in children are limited [<a href="#rid95">95-97</a>]. Support is provided predominantly by in vitro studies [<a href="#rid98">98,99</a>], a randomized trial in military recruits [<a href="#rid100">100</a>], and observational studies in which inclusion of <em>M. pneumoniae</em>-specific therapy was associated with decreased risk of treatment failure (ie, change in antimicrobial therapy or hospital admission) or length of stay in children with CAP (etiologic data were not available) [<a href="#rid62">62,101</a>]. A systematic review of 17 studies (4294 patients) found insufficient evidence for efficacy of antimicrobial treatment of <em>M. pneumoniae</em> lower respiratory tract infection in children ≤17 years [<a href="#rid97">97</a>]. However, the included trials were limited by publication bias, heterogeneity, and lack of blinding [<a href="#rid97">97,102</a>].</p><p>Whether administration of antibiotics decreases the incidence or severity of associated mucocutaneous disease is unclear [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H7342929"><span class="h3">Macrolide resistance</span><span class="headingEndMark"> — </span>The possibility of macrolide resistance should be considered in children with suspected <em>M. pneumoniae</em> infection who do not respond as expected to macrolide therapy, particularly if the child is severely ill and/or has a history of exposure to a macrolide [<a href="#rid24">24</a>].</p><p><em>M. pneumoniae</em> resistant to macrolides has been reported in Asia, Europe, and North America [<a href="#rid104">104-112</a>]. In the United States, in studies published from 2010 to 2019, macrolide resistance ranges from 3.5 to 13.2 percent of <em>M. pneumoniae</em> isolates [<a href="#rid22">22,24,111,113</a>]. In a 2015 to 2018 study, the overall rate of macrolide resistance from eight hospitals in the United States was 7.5 percent [<a href="#rid24">24</a>]. However, resistance varied geographically, from 2 percent in the West to 18 percent in the South and East.</p><p>In some studies, prolonged fever (ie, ≥48 hours after the initiation of therapy) has been reported in children with macrolide-resistant isolates who were treated with macrolide antibiotics [<a href="#rid107">107,114-117</a>]. Another study found no differences in clinical features or outcome between patients with macrolide-resistant and macrolide-susceptible <em>M. pneumoniae</em>, but there were few children with macrolide-resistant <em>M. pneumoniae </em>(21 versus 285)<em> </em>[<a href="#rid24">24</a>].</p><p>Rapid testing methods for detection of macrolide resistance have been developed and are available in some clinical laboratories [<a href="#rid2">2</a>].</p><p>For children with documented or suspected <em>M. pneumoniae</em> pneumonia who do not respond as expected to macrolide therapy, we suggest a tetracycline antibiotic (eg, <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a>, <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">doxycycline</a>) or fluoroquinolone (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>) antibiotic [<a href="#rid98">98,109</a>]. We suggest one of the following regimens [<a href="#rid88">88,90,118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">Doxycycline</a> 2 to 4 mg/kg orally or IV per day in one or two divided doses (maximum daily dose 200 mg) for 10 days; compared with other tetracycline antibiotics, doxycycline is unlikely to cause permanent tooth discoloration in young children [<a href="#rid91">91-94</a>]. It can be administered for ≤21 days to children of all ages [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥6 months and &lt;5 years – 8 to 10 mg/kg per dose every 12 hours (maximum daily dose 750 mg/day) for 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥5 years – 10 mg/kg per dose once per day (maximum daily dose 750 mg/day) for 7 to 10 days</p><p></p><p class="bulletIndent1">Although fluoroquinolones are not routine first-line agents for children, they may be reasonable if no other safe and effective alternative is available [<a href="#rid87">87,88</a>]. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p></p><p class="headingAnchor" id="H2039237421"><span class="h2">Other clinical syndromes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper respiratory tract infections</strong> – We do not treat <em>M. pneumoniae</em> upper respiratory tract infections with antibiotics. The benefits of antimicrobial therapy for the treatment of upper respiratory tract symptoms caused by <em>M. pneumoniae </em>have not been adequately studied in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucocutaneous disease</strong> – Consultation with a specialist in dermatology or infectious diseases may be warranted to differentiate reactive infectious mucocutaneous eruption (RIME) from other mucocutaneous eruptions [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1">The management of RIME is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/120346.html" rel="external">"Reactive infectious mucocutaneous eruption (RIME)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1">Treatment of associated pneumonia (if present) is discussed above [<a href="#rid120">120</a>]. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system disease</strong> – Treatment of <em>M. pneumoniae</em> central nervous system (CNS) disease is individualized according to the clinical syndrome (eg, encephalitis, Guillain-Barré syndrome) and severity of illness. Consultation with an expert in pediatric infectious diseases and/or pediatric neurology is suggested.</p><p></p><p class="bulletIndent1">Antibiotics and adjunctive therapies to address immune-mediated symptoms may have a therapeutic role and are frequently administered given concern for long-term neurologic sequelae. However, randomized trials evaluating antimicrobial and/or adjunctive therapies for <em>M. pneumoniae</em> CNS disease are lacking. In observational studies, glucocorticoids, anti-inflammatory drugs, diuretics, intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a>, and plasma exchange have been used in addition to antibiotics without clear indication of benefit [<a href="#rid12">12,42,47,121,122</a>]. As an example, in a retrospective analysis of 42 children with definite, probable, or possible <em>M. pneumoniae</em> CNS disease (eg, encephalitis, transverse myelitis, acute disseminated encephalomyelitis), 29 children received macrolide therapy and 17 received glucocorticoids [<a href="#rid47">47</a>]. Adverse neurologic outcome (eg, epilepsy, focal neurologic deficit) occurred in 15 of those who received macrolides and 9 of those who received glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic anemia</strong> – The management of <em>M. pneumoniae</em>-related hemolytic anemia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H2290625835"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110776.html" rel="external">"Society guideline links: Pediatric pneumonia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109959.html" rel="external">"Society guideline links: Infectious encephalitis"</a>.)</p><p class="headingAnchor" id="H8578675"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17120.html" rel="external">"Patient education: Pneumonia in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/87113.html" rel="external">"Patient education: Mycoplasma pneumonia in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycoplasma pneumoniae </em>is fastidious bacteria that lacks a cell wall. It is transmitted from person to person by infected respiratory droplets. The incubation period is approximately three weeks and the cumulative attack rate in families approaches 90 percent. (See <a class="local">'Microbiology and pathogenesis'</a> above and <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em> infection occurs in children of all ages and is a common cause of community-acquired pneumonia (CAP) in children, particularly those ≥5 years of age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em> CAP has a gradual onset and usually is heralded by headache, malaise, and low-grade fever  (<a class="graphic graphic_figure graphicRef59329" href="/z/d/graphic/59329.html" rel="external">figure 1</a>). <em>M. pneumoniae</em> CAP may be accompanied by other respiratory tract findings (eg, pharyngitis) and extrapulmonary manifestations (eg, hemolysis, mucocutaneous eruption, central nervous system involvement). Clinical, radiographic, and laboratory features are nonspecific and do not definitively distinguish <em>M. pneumoniae</em> from other CAP pathogens. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em> mucocutaneous disease is increasingly recognized in adolescents. It predominantly affects the mucous membranes and usually is associated with atypical CAP. (See <a class="local">'Mucocutaneous disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em> should be suspected in children with a compatible clinical syndrome. Laboratory confirmation requires detection of <em>M. pneumoniae</em> or antibody response to <em>M. pneumoniae</em> but should only be pursued if it will alter management (eg, if antimicrobial therapy is necessary and the empiric regimen does not include an agent with activity against <em>M. pneumoniae</em>, such as a macrolide or <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> antibiotic). (See <a class="local">'Indications for testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to testing varies with the clinical syndrome. When testing is necessary, we generally prefer <em>M. pneumoniae</em> polymerase chain reaction (PCR) from a respiratory specimen. It can be performed rapidly and has high sensitivity and specificity. If PCR is not available, serology (IgM and IgG enzyme immunoassay) is a reasonable alternative. (See <a class="local">'Approach to testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with documented <em>M. pneumoniae </em>pneumonia, we suggest antimicrobial therapy with an agent with activity against <em>M. pneumoniae </em>(eg, macrolide, <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a>, or fluoroquinolone antibiotics) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)<em>.</em> Limited evidence suggests that <em>M. pneumoniae</em>-specific therapy may be associated with decreased rates of hospitalization or shorter length of stay. For immunocompetent children, we prefer macrolide or tetracycline antibiotics to fluoroquinolones. For immunocompromised children, fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>) are another alternative, especially if the patient has a history of exposure to a macrolide antibiotic. (See <a class="local">'Documented M. pneumoniae'</a> above.)</p><p></p><p class="bulletIndent1">The regimens are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">Azithromycin</a> 10 mg/kg in one dose (maximum dose 500 mg) orally or intravenously (IV) on the first day and 5 mg/kg in one dose (maximum dose 250 mg) for the next four days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13165" href="/z/d/drug information/13165.html" rel="external">Clarithromycin</a> 15 mg/kg per day orally in two divided doses (maximum daily dose 1 g) for 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">Doxycycline</a> 2 to 4 mg/kg per day orally or IV in one or two divided doses (maximum daily dose 200 mg) for 7 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">Erythromycin</a> 40 to 50 mg/kg per day orally in three or four divided doses (maximum daily dose 2 g) for 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">Erythromycin</a> 20 mg/kg per day IV in four divided doses (maximum daily dose 2 g) for 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥8 years of age: <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a> 20 to 50 mg/kg per day orally in four divided doses (maximum daily dose 2 g) for 7 to 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥6 months and &lt;5 years – <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> 8 to 10 mg/kg per dose orally or IV every 12 hours (maximum daily dose 750 mg/day) for 7 to 10 days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥5 years – <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">Levofloxacin</a> 10 mg/kg per dose once per day orally or IV (maximum daily dose 750 mg/day) for 7 to 10 days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">Doxycycline</a> or a fluoroquinolone (eg, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>) antibiotic should be used if macrolide resistance is suspected or documented, particularly if the child is severely ill. (See <a class="local">'Macrolide resistance'</a> above.)</p><p></p><p class="headingAnchor" id="H4154234508"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dori Zaleznik, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shah SS. Mycoplasma pneumoniae as a Cause of Community-Acquired Pneumonia in Children. Clin Infect Dis 2019; 68:13.</a></li><li><a class="nounderline abstract_t">Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017; 30:747.</a></li><li><a class="nounderline abstract_t">Narita M. Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis. Front Microbiol 2016; 7:23.</a></li><li><a class="nounderline abstract_t">Krause DC, Balish MF. Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae. Mol Microbiol 2004; 51:917.</a></li><li><a class="nounderline abstract_t">Page CA, Krause DC. Protein kinase/phosphatase function correlates with gliding motility in Mycoplasma pneumoniae. J Bacteriol 2013; 195:1750.</a></li><li><a class="nounderline abstract_t">Chang HY, Jordan JL, Krause DC. Domain analysis of protein P30 in Mycoplasma pneumoniae cytadherence and gliding motility. J Bacteriol 2011; 193:1726.</a></li><li><a class="nounderline abstract_t">Chang HY, Prince OA, Sheppard ES, Krause DC. Processing is required for a fully functional protein P30 in Mycoplasma pneumoniae gliding and cytadherence. J Bacteriol 2011; 193:5841.</a></li><li><a class="nounderline abstract_t">Seya T, Matsumoto M. A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. Int J Biochem Cell Biol 2002; 34:901.</a></li><li><a class="nounderline abstract_t">Lührmann A, Deiters U, Skokowa J, et al. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect Immun 2002; 70:3785.</a></li><li><a class="nounderline abstract_t">Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokine Growth Factor Rev 2004; 15:157.</a></li><li><a class="nounderline abstract_t">Feizi T, Loveless RW. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Am J Respir Crit Care Med 1996; 154:S133.</a></li><li><a class="nounderline abstract_t">Baseman JB, Reddy SP, Dallo SF. Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Am J Respir Crit Care Med 1996; 154:S137.</a></li><li><a class="nounderline abstract_t">Yavlovich A, Tarshis M, Rottem S. Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells. FEMS Microbiol Lett 2004; 233:241.</a></li><li><a class="nounderline abstract_t">Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10:e1001444.</a></li><li><a class="nounderline abstract_t">Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol 2008; 8:93.</a></li><li><a class="nounderline abstract_t">Prince OA, Krunkosky TM, Sheppard ES, Krause DC. Modelling persistent Mycoplasma pneumoniae infection of human airway epithelium. Cell Microbiol 2018; 20.</a></li><li><a class="nounderline abstract_t">Luby JP. Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med 1991; 12:237.</a></li><li><a class="nounderline abstract_t">Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979; 139:681.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Unger WWJ, van Rossum AMC, Berger C. The Art and Science of Diagnosing Mycoplasma pneumoniae Infection. Pediatr Infect Dis J 2018; 37:1192.</a></li><li><a class="nounderline abstract_t">Gordon O, Oster Y, Michael-Gayego A, et al. The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort. Pediatr Infect Dis J 2019; 38:698.</a></li><li><a class="nounderline abstract_t">Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.</a></li><li><a class="nounderline abstract_t">Kutty PK, Jain S, Taylor TH, et al. Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis 2019; 68:5.</a></li><li><a class="nounderline abstract_t">Han MS, Yun KW, Lee HJ, et al. Contribution of Co-detected Respiratory Viruses and Patient Age to the Clinical Manifestations of Mycoplasma Pneumoniae Pneumonia in Children. Pediatr Infect Dis J 2018; 37:531.</a></li><li><a class="nounderline abstract_t">Waites KB, Ratliff A, Crabb DM, et al. Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Denny FW, Clyde WA Jr, Glezen WP. Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control. J Infect Dis 1971; 123:74.</a></li><li><a class="nounderline abstract_t">Clyde WA Jr. Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis 1993; 17 Suppl 1:S32.</a></li><li><a class="nounderline abstract_t">Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334.</a></li><li><a class="nounderline abstract_t">Wang K, Gill P, Perera R, et al. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev 2012; 10:CD009175.</a></li><li><a class="nounderline abstract_t">Dorigo-Zetsma JW, Wilbrink B, van der Nat H, et al. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis 2001; 183:675.</a></li><li><a class="nounderline abstract_t">Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol 2015; 53:124.</a></li><li><a class="nounderline abstract_t">Palma S C, Martínez T MA, Salinas S M, Rojas G P. [Asymptomatic pharyngeal carriage of Mycoplasma pneumoniae in Chilean children]. Rev Chilena Infectol 2005; 22:247.</a></li><li><a class="nounderline abstract_t">Wood PR, Hill VL, Burks ML, et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Ann Allergy Asthma Immunol 2013; 110:328.</a></li><li><a class="nounderline abstract_t">Kannan TR, Hardy RD, Coalson JJ, et al. Fatal outcomes in family transmission of Mycoplasma pneumoniae. Clin Infect Dis 2012; 54:225.</a></li><li><a class="nounderline abstract_t">Moynihan KM, Barlow A, Nourse C, et al. Severe Mycoplasma Pneumoniae Infection in Children Admitted to Pediatric Intensive Care. Pediatr Infect Dis J 2018; 37:e336.</a></li><li><a class="nounderline abstract_t">Cheong KN, Chiu SS, Chan BW, et al. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect 2016; 49:127.</a></li><li><a class="nounderline abstract_t">Reittner P, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol 2000; 174:37.</a></li><li><a class="nounderline abstract_t">Zafer MH, Gamel AS, Ansari MA, Hamid ME. Anemic crisis due to Mycoplasma pneumoniae complication in sickle cell patients. Saudi Med J 2009; 30:157.</a></li><li><a class="nounderline abstract_t">Schalock PC, Dinulos JG. Mycoplasma pneumoniae-induced cutaneous disease. Int J Dermatol 2009; 48:673.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Theiler M, Buettcher M, et al. Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia. JAMA Dermatol 2020; 156:144.</a></li><li><a class="nounderline abstract_t">Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis 1993; 17 Suppl 1:S52.</a></li><li><a class="nounderline abstract_t">Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila) 2000; 39:195.</a></li><li><a class="nounderline abstract_t">Candler PM, Dale RC. Three cases of central nervous system complications associated with Mycoplasma pneumoniae. Pediatr Neurol 2004; 31:133.</a></li><li><a class="nounderline abstract_t">Christie LJ, Honarmand S, Talkington DF, et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 2007; 120:305.</a></li><li><a class="nounderline abstract_t">Walter ND, Grant GB, Bandy U, et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. J Infect Dis 2008; 198:1365.</a></li><li><a class="nounderline abstract_t">Weng WC, Peng SS, Wang SB, et al. Mycoplasma pneumoniae--associated transverse myelitis and rhabdomyolysis. Pediatr Neurol 2009; 40:128.</a></li><li><a class="nounderline abstract_t">Lin JJ, Hsia SH, Wu CT, et al. Mycoplasma pneumoniae-related postencephalitic epilepsy in children. Epilepsia 2011; 52:1979.</a></li><li><a class="nounderline abstract_t">Al-Zaidy SA, MacGregor D, Mahant S, et al. Neurological Complications of PCR-Proven M. pneumoniae Infections in Children: Prodromal Illness Duration May Reflect Pathogenetic Mechanism. Clin Infect Dis 2015; 61:1092.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: A case-control study. Ann Neurol 2016; 80:566.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Roodbol J, Hackenberg A, et al. Severe childhood Guillain-Barré syndrome associated with Mycoplasma pneumoniae infection: a case series. J Peripher Nerv Syst 2015; 20:72.</a></li><li><a class="nounderline abstract_t">Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001; 32:1674.</a></li><li><a class="nounderline abstract_t">Domenech C, Leveque N, Lina B, et al. Role of Mycoplasma pneumoniae in pediatric encephalitis. Eur J Clin Microbiol Infect Dis 2009; 28:91.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Jacobs BC, Spuesens EB, et al. Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS Pathog 2014; 10:e1003983.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Moeller A, Relly C, et al. Swiss national prospective surveillance of paediatric Mycoplasma pneumoniae-associated encephalitis. Swiss Med Wkly 2016; 146:w14222.</a></li><li><a class="nounderline abstract_t">Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5:585.</a></li><li><a class="nounderline abstract_t">Saïd MH, Layani MP, Colon S, et al. Mycoplasma pneumoniae-associated nephritis in children. Pediatr Nephrol 1999; 13:39.</a></li><li><a class="nounderline abstract_t">Hirano D, Oda T, Ito A, et al. Glyceraldehyde-3-phosphate dehydrogenase of Mycoplasma pneumoniae induces infection-related glomerulonephritis . Clin Nephrol 2019; 92:263.</a></li><li><a class="nounderline abstract_t">Laso Mdel C, Cadario ME, Haymes L, et al. Mycoplasma pneumoniae detection with PCR in renal tissue of a patient with acute glomerulonephritis. Pediatr Nephrol 2006; 21:1483.</a></li><li><a class="nounderline abstract_t">Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</a></li><li><a class="nounderline abstract_t">Touati A, Benard A, Hassen AB, et al. Evaluation of five commercial real-time PCR assays for detection of Mycoplasma pneumoniae in respiratory tract specimens. J Clin Microbiol 2009; 47:2269.</a></li><li><a class="nounderline abstract_t">Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis 2010; 29:1055.</a></li><li><a class="nounderline abstract_t">Ambroggio L, Test M, Metlay JP, et al. Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting. Pediatr Infect Dis J 2015; 34:839.</a></li><li><a class="nounderline abstract_t">Ambroggio L, Test M, Metlay JP, et al. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol 2016; 51:541.</a></li><li><a class="nounderline abstract_t">Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.</a></li><li><a class="nounderline abstract_t">Roy Chowdhury S. Mycoplasma pneumoniae-induced rash and mucositis is a distinct entity that needs more recognition. J Paediatr Child Health 2020; 56:645.</a></li><li><a class="nounderline abstract_t">Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013; 57:1114.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Mycoplasma pneumoniae outbreak at a university - Georgia, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:603.</a></li><li><a class="nounderline abstract_t">Szymanski M, Petric M, Saunders FE, Tellier R. Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy. Clin Infect Dis 2002; 34:E16.</a></li><li><a class="nounderline abstract_t">Chaudhry R, Nisar N, Malhotra P, et al. Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis: a case report. Indian J Pathol Microbiol 2003; 46:433.</a></li><li><a class="nounderline abstract_t">Davis CP, Cochran S, Lisse J, et al. Isolation of Mycoplasma pneumoniae from synovial fluid samples in a patient with pneumonia and polyarthritis. Arch Intern Med 1988; 148:969.</a></li><li><a class="nounderline abstract_t">Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740.</a></li><li><a class="nounderline abstract_t">Thurman KA, Walter ND, Schwartz SB, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 2009; 48:1244.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Mycoplasma pneumoniae infections. Diagnostic methods. Available at: https://www.cdc.gov/pneumonia/atypical/mycoplasma/hcp/diagnostic-methods.html (Accessed on October 15, 2019).</li><li><a class="nounderline abstract_t">Xu D, Li S, Chen Z, Du L. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr 2011; 170:851.</a></li><li class="breakAll">American Academy of Pediatrics. Mycoplasma pneumoniae and other Mycoplasma species infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.543.</li><li class="breakAll">US Food and Drug Administration (FDA) News Release. FDA expands use for FilmArray Respiratory Panel. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm (Accessed on June 11, 2012).</li><li><a class="nounderline abstract_t">Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011; 6:e26047.</a></li><li><a class="nounderline abstract_t">Blackmore TK, Reznikov M, Gordon DL. Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection. Pathology 1995; 27:177.</a></li><li><a class="nounderline abstract_t">Waring AL, Halse TA, Csiza CK, et al. Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State. J Clin Microbiol 2001; 39:1385.</a></li><li><a class="nounderline abstract_t">Kanwar N, Pence MA, Mayne D, et al. Evaluation of the illumigene Mycoplasma Direct DNA Amplification Assay. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003; 9:263.</a></li><li><a class="nounderline abstract_t">Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697.</a></li><li><a class="nounderline abstract_t">Nir-Paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect 2006; 12:685.</a></li><li><a class="nounderline abstract_t">Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005; 43:2277.</a></li><li><a class="nounderline abstract_t">Talkington DF, Shott S, Fallon MT, et al. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004; 11:862.</a></li><li><a class="nounderline abstract_t">Busson L, Van den Wijngaert S, Dahma H, et al. Evaluation of 10 serological assays for diagnosing Mycoplasma pneumoniae infection. Diagn Microbiol Infect Dis 2013; 76:133.</a></li><li><a class="nounderline abstract_t">Marmion BP, Williamson J, Worswick DA, et al. Experience with newer techniques for the laboratory detection of Mycoplasma pneumoniae infection: Adelaide, 1978-1992. Clin Infect Dis 1993; 17 Suppl 1:S90.</a></li><li class="breakAll">US Food and Drug Administration. FDA Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 13, 2016).</li><li><a class="nounderline abstract_t">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.</a></li><li class="breakAll">American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.876.</li><li><a class="nounderline abstract_t">Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr 2015; 166:1246.</a></li><li><a class="nounderline abstract_t">Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf 2016; 15:367.</a></li><li><a class="nounderline abstract_t">Pöyhönen H, Nurmi M, Peltola V, et al. Dental staining after doxycycline use in children. J Antimicrob Chemother 2017; 72:2887.</a></li><li class="breakAll">American Academy of Pediatrics. Tetracyclines. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.866.</li><li><a class="nounderline abstract_t">Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2015; 1:CD004875.</a></li><li><a class="nounderline abstract_t">Blyth CC, Gerber JS. Macrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo? J Pediatric Infect Dis Soc 2018; 7:71.</a></li><li><a class="nounderline abstract_t">Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics 2014; 133:1081.</a></li><li><a class="nounderline abstract_t">Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423.</a></li><li><a class="nounderline abstract_t">Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214.</a></li><li><a class="nounderline abstract_t">KINGSTON JR, CHANOCK RM, MUFSON MA, et al. Eaton agent pneumonia. JAMA 1961; 176:118.</a></li><li><a class="nounderline abstract_t">Ambroggio L, Taylor JA, Tabb LP, et al. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia. J Pediatr 2012; 161:1097.</a></li><li><a class="nounderline abstract_t">Colin AA, Yousef S, Forno E, Korppi M. Treatment of Mycoplasma pneumoniae in pediatric lower respiratory infection. Pediatrics 2014; 133:1124.</a></li><li><a class="nounderline abstract_t">Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72:239.</a></li><li><a class="nounderline abstract_t">Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52.</a></li><li><a class="nounderline abstract_t">Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011; 17:1079.</a></li><li><a class="nounderline abstract_t">Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17:354.</a></li><li><a class="nounderline abstract_t">Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66:734.</a></li><li><a class="nounderline abstract_t">Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 55:1642.</a></li><li><a class="nounderline abstract_t">Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013; 57:4046.</a></li><li><a class="nounderline abstract_t">Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 2015; 21:1470.</a></li><li><a class="nounderline abstract_t">Kim K, Jung S, Kim M, et al. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2220949.</a></li><li><a class="nounderline abstract_t">Diaz MH, Benitez AJ, Cross KE, et al. Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infect Dis 2015; 2:ofv106.</a></li><li><a class="nounderline abstract_t">Yoo SJ, Kim HB, Choi SH, et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob Agents Chemother 2012; 56:6393.</a></li><li><a class="nounderline abstract_t">Ma Z, Zheng Y, Deng J, et al. Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China. Pediatr Pulmonol 2014; 49:695.</a></li><li><a class="nounderline abstract_t">Cardinale F, Chironna M, Chinellato I, et al. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol 2013; 51:723.</a></li><li><a class="nounderline abstract_t">Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006; 50:709.</a></li><li><a class="nounderline abstract_t">Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45:153.</a></li><li class="breakAll">Frantz GF, McAninch SA. Mycoplasma mucositis. StatPearls. Treasure Island, FL, StatPearls Publishing, 2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK525960/ (Accessed on October 23, 2019).</li><li><a class="nounderline abstract_t">Latsch K, Girschick HJ, Abele-Horn M. Stevens-Johnson syndrome without skin lesions. J Med Microbiol 2007; 56:1696.</a></li><li><a class="nounderline abstract_t">Daxboeck F. Mycoplasma pneumoniae central nervous system infections. Curr Opin Neurol 2006; 19:374.</a></li><li><a class="nounderline abstract_t">Daba M, Kang PB, Sladky J, et al. Intravenous Immunoglobulin as a Therapeutic Option for Mycoplasma pneumoniae Encephalitis. J Child Neurol 2019; 34:687.</a></li></ol></div><div id="topicVersionRevision">Topic 6070 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788200" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mycoplasma pneumoniae as a Cause of Community-Acquired Pneumonia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28539503" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mycoplasma pneumoniae from the Respiratory Tract and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858701" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14763969" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23396910" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Protein kinase/phosphatase function correlates with gliding motility in Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257768" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Domain analysis of protein P30 in Mycoplasma pneumoniae cytadherence and gliding motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821772" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Processing is required for a fully functional protein P30 in Mycoplasma pneumoniae gliding and cytadherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12007626" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065522" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110799" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cytokines in Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876531" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876532" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063492" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690754" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547431" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29155483" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Modelling persistent Mycoplasma pneumoniae infection of human airway epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906790" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pneumonia caused by Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/448195" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-term epidemiology of infections with Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169485" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Art and Science of Diagnosing Mycoplasma pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25714161" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Community-acquired pneumonia requiring hospitalization among U.S. children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788037" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mycoplasma pneumoniae Among Children Hospitalized With Community-acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29095244" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Contribution of Co-detected Respiratory Viruses and Patient Age to the Clinical Manifestations of Mycoplasma Pneumoniae Pneumonia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31484701" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5100980" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399935" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical overview of typical Mycoplasma pneumoniae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11871806" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076954" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170998" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355769" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077892" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Asymptomatic pharyngeal carriage of Mycoplasma pneumoniae in Chilean children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23622002" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mycoplasma pneumoniae in children with acute and refractory asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22052890" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fatal outcomes in family transmission of Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912842" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Severe Mycoplasma Pneumoniae Infection in Children Admitted to Pediatric Intensive Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25556047" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10628450" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139793" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anemic crisis due to Mycoplasma pneumoniae complication in sickle cell patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570071" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mycoplasma pneumoniae-induced cutaneous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851288" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399938" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10791130" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301835" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Three cases of central nervous system complications associated with Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671056" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pediatric encephalitis: what is the role of Mycoplasma pneumoniae?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808334" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135630" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mycoplasma pneumoniae--associated transverse myelitis and rhabdomyolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21838790" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mycoplasma pneumoniae-related postencephalitic epilepsy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26084846" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neurological Complications of PCR-Proven M. pneumoniae Infections in Children: Prodromal Illness Duration May Reflect Pathogenetic Mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490360" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mycoplasma pneumoniae triggering the Guillain-Barrésyndrome: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115201" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Severe childhood Guillain-Barrésyndrome associated with Mycoplasma pneumoniae infection: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360206" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute childhood encephalitis and Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626673" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Role of Mycoplasma pneumoniae in pediatric encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945969" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26752230" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Swiss national prospective surveillance of paediatric Mycoplasma pneumoniae-associated encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955701" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Atypical pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10100287" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mycoplasma pneumoniae-associated nephritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31496514" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glyceraldehyde-3-phosphate dehydrogenase of Mycoplasma pneumoniae induces infection-related glomerulonephritis .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16819643" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mycoplasma pneumoniae detection with PCR in renal tissue of a patient with acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880587" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19403761" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of five commercial real-time PCR assays for detection of Mycoplasma pneumoniae in respiratory tract specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526788" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25955834" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26367389" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517420" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mycoplasma pneumoniae-induced rash and mucositis is a distinct entity that needs more recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861361" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23903594" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycoplasma pneumoniae outbreak at a university - Georgia, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731968" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15025294" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Polymerase chain reaction confirmed Mycoplasma pneumoniae arthritis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3128197" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Isolation of Mycoplasma pneumoniae from synovial fluid samples in a patient with pneumonia and polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672205" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331586" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331586" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107602" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Detection of Mycoplasma pneumoniae in different respiratory specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107602" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Detection of Mycoplasma pneumoniae in different respiratory specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107602" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Detection of Mycoplasma pneumoniae in different respiratory specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039434" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567149" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283060" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29720432" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Evaluation of the illumigene Mycoplasma Direct DNA Amplification Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12667235" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Laboratory diagnosis of Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489344" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mycoplasma pneumoniae and its role as a human pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16774570" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15872256" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358644" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537789" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Evaluation of 10 serological assays for diagnosing Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399945" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Experience with newer techniques for the laboratory detection of Mycoplasma pneumoniae infection: Adelaide, 1978-1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399945" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Experience with newer techniques for the laboratory detection of Mycoplasma pneumoniae infection: Adelaide, 1978-1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667050" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667050" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794784" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680308" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091225" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Dental staining after doxycycline use in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566754" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096010" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Macrolides in Children With Community-Acquired Pneumonia: Panacea or Placebo?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864174" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of mycoplasma pneumonia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21526943" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mycoplasma pneumoniae: susceptibility and resistance to antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047413" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13756133" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Eaton agent pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901738" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparative effectiveness of empiricβ-lactam monotherapy andβ-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864169" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Treatment of Mycoplasma pneumoniae in pediatric lower respiratory infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592340" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429926" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21749775" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22209916" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077195" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393214" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972867" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716043" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196107" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Macrolide-Resistant Mycoplasma pneumoniae, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816304" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26284257" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23006753" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861188" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224091" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436730" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647407" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Levofloxacin pharmacokinetics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647407" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Levofloxacin pharmacokinetics in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18033843" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Stevens-Johnson syndrome without skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914976" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Mycoplasma pneumoniae central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31185782" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intravenous Immunoglobulin as a Therapeutic Option for Mycoplasma pneumoniae Encephalitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
